Artificial Oocyte Activation

Clinique Ovo54 enrolled

Overview

Studies reported that calcium signal deficiency or insufficiency during oocyte activation are related with embryo arrest and blastocyst quality. The utilization of Artificial Oocyte Activation (AOA) is safe and does not increase birth defects, cognition, language and motor skills. AOA is the first line of treatment in patients with globozoospermia (round headed spermatozoa). Poor responders in in-vitro fertilization (IVF) cycles represent a major challenge for fertility specialists and comprises about 10-15% of patients undergoing controlled ovarian hyperstimulation. The absence of synergy between the oocyte and sperm leads to a negative impact on oocyte activation. The European Society of Human and REproduction (ESHRE) recommends AOA in cases with failed fertilization/ low fertilization.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Infertility Ovarian Insufficiency

Interventions

women having had a second IVF cycle with AOAOTHER

The absence of synergy between the oocyte and sperm leads to a negative impact on oocyte activation. Physiological oocyte activation requires a sperm-derived enzyme called phospholipase C zeta to cause the release of calcium in the form of oscillations from internal storages.

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 42 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with poor or no blastocyst development in their primary cycle * Group 1 - second cycle using AOA following the poor blastocyst development cycle * Group 2 - second cycle without AOA following the poor development cycle Exclusion Criteria: * All cycles who do not have repeat cycles following the poor blastocyst development cycle

Outcomes

Primary Outcomes

Blastocyst rate

Likelihood of an oocyte fertilized to blastocyst stage

Time frame: 5 days after oocyte fertilization